NasdaqGS - Nasdaq Real Time Price USD

Axonics, Inc. (AXNX)

Compare
68.84 -0.26 (-0.38%)
At close: September 5 at 4:00 PM EDT
68.84 0.00 (0.00%)
After hours: September 5 at 4:20 PM EDT
Loading Chart for AXNX
DELL
  • Previous Close 69.10
  • Open 69.19
  • Bid 49.75 x 200
  • Ask 88.69 x 200
  • Day's Range 68.70 - 69.19
  • 52 Week Range 48.30 - 69.68
  • Volume 558,927
  • Avg. Volume 336,273
  • Market Cap (intraday) 3.519B
  • Beta (5Y Monthly) 0.82
  • PE Ratio (TTM) --
  • EPS (TTM) -0.02
  • Earnings Date Oct 28, 2024 - Nov 1, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

www.axonics.com

797

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AXNX

View More

Research Reports: AXNX

View More

Performance Overview: AXNX

Trailing total returns as of 9/5/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AXNX
10.62%
S&P 500
15.38%

1-Year Return

AXNX
18.69%
S&P 500
21.87%

3-Year Return

AXNX
10.84%
S&P 500
21.34%

5-Year Return

AXNX
107.85%
S&P 500
87.33%

Compare To: AXNX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AXNX

View More

Valuation Measures

Annual
As of 9/5/2024
  • Market Cap

    3.52B

  • Enterprise Value

    3.21B

  • Trailing P/E

    --

  • Forward P/E

    161.29

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    8.45

  • Price/Book (mrq)

    5.47

  • Enterprise Value/Revenue

    7.85

  • Enterprise Value/EBITDA

    333.70

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -0.42%

  • Return on Assets (ttm)

    -0.46%

  • Return on Equity (ttm)

    -0.27%

  • Revenue (ttm)

    408.81M

  • Net Income Avi to Common (ttm)

    -1.71M

  • Diluted EPS (ttm)

    -0.02

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    343.41M

  • Total Debt/Equity (mrq)

    5.05%

  • Levered Free Cash Flow (ttm)

    24.39M

Research Analysis: AXNX

View More

Company Insights: AXNX

People Also Watch